Publications by authors named "Onur Yazdan Balcık"
Article Synopsis
- Bladder carcinoma (BC) is common, with 20% classified as non-muscle invasive bladder cancer (NMIBC), where about 40% of patients experience recurrence despite treatment.
- The study evaluates the prognostic implications of FOXP3, TIM-3, and tertiary lymphoid structures (TLS) in NMIBC by analyzing patient samples using immunohistochemistry and survival analysis.
- Findings indicate that higher levels of FOXP3/TLS correlate with better recurrence-free survival, suggesting that FOXP3/TLS may serve as an effective prognostic marker, especially for patients undergoing BCG treatment.
Article Synopsis
- The study compared the effectiveness and safety of FOLFIRI combined with bevacizumab versus FOLFIRI combined with aflibercept in patients with RAS-mutant metastatic colon cancer who had previously received treatment.
- Results showed that patients receiving FOLFIRI with bevacizumab had a median overall survival (OS) of 14.1 months and progression-free survival (PFS) of 7.7 months, which were significantly better than those treated with aflibercept (OS: 11.2 months, PFS: 5.7 months).
- Additionally, the bevacizumab group experienced fewer severe side effects (50.9% in aflibercept group vs 25.
Lung cancer is the leading cause of cancer-related death globally and is often diagnosed at an advanced stage. Nivolumab represents a significant advancement for treating advanced non-small cell lung cancer (NSCLC). However, the absence of reliable biomarkers predicting treatment response hinders personalized therapy.
View Article and Find Full Text PDFObjective: The pivotal prognostic determinant for recurrence and survival in surgically treated gastric cancer (GC) patients remains the lymph node status. Despite the adoption of D2 lymph node dissection as the standard approach in recent years, its association with increased morbidity in elderly patients raises concerns. This study aims to explore the prognostic significance of the Positive Lymph Node Ratio (PLNR) score in the context of recurrence and survival among elderly patients with surgically treated GC.
View Article and Find Full Text PDFPurpose: In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness and safety of using granulocyte-colony stimulating factor (G-CSF) as a preventive treatment during chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC).
- A total of 119 patients were analyzed, comparing those who received G-CSF to those who did not, with results indicating better response and disease control rates in the G-CSF group, although the differences were not statistically significant.
- Overall, using G-CSF alongside the treatment protocol did not significantly improve efficacy or increase side effects, suggesting it can be safely integrated into treatment for ES-SCLC patients.
Introduction: Several prognostic factors have been identified in patients with metastatic bladder cancer (BC). As it is known, older adult patients are prone to nutritional deficiency. The knowledge about nutrition and impact on survival in older patients with metastatic bladder cancer is missing.
View Article and Find Full Text PDFBackground: The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall survival (OS) compared to placebo. In real-world practice chemotherapy rechallenge is also a preferred option even though supporting evidence is not enough.
View Article and Find Full Text PDFObjective: To evaluate the prognostic significance of the new index designed by formulating neutrophil, lymphocyte, and platelet counts in patients with metastatic disease receiving immune checkpoint inhibitors (ICI) and its effect on the immune-related adverse events (irAEs).
Study Design: Cohort study.
Place And Duration Of Study: Department of Medical Oncology, University of Manisa Celal Bayar, University of Aydin Adnan Menderes, and University of Ege, and Izmir Kent Hospital, Turkey, from January 2016 to April 2020.
HALP Score as a New Prognostic Index in Metastatic Renal Cell Cancer.
J Coll Physicians Surg Pak
March 2022
Objective: To evaluate prognostic significance of the new index, designed by formulating hemoglobin, albumin, lymphocyte, and platelet (HALP) counts in patients with metastatic renal cell carcinoma (RCC).
Study Design: Descriptive study.
Place And Duration Of Study: Department of Medical Oncology, Celal Bayar University, Manisa, Turkey and Adnan Menderes University, Aydin, Turkey, from January 2014 to April 2020.
Purpose: To investigate the clinical importance of the inflammatory prognostic index (IPI) in patients with metastatic colorectal cancer treated with regorafenib.
Methods: A retrospective analysis of 65 metastatic CRC patients treated with regorafenib between 2015 and 2020 was performed. The association between NLR, PNLR, IPI, and overall survival (OS) and progression-free survival (PFS) was evaluated.